SCHEMBL7568797

SCHEMBL7568797

Cc1ccc(S(=O)(=O)OC(=NNc2cccc(C#N)c2)C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY2 P41231 1/20 0.42
GPR17 Q13304 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
SLC22A12 Q96S37 1/20 0.39
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
RORC P51449 1/20 0.38
FFAR1 O14842 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7637263 1.00 P2RY2 (0.42) P2RY2GPR17POLBSMN1; SMN2PDK1
SCHEMBL7474554 0.86 P2RY2 (0.44) P2RY2GPR17POLBSMN1; SMN2IDO1
SCHEMBL7568763 0.84 PDK1 (0.45) POLBSMN1; SMN2PDK1PDK2PDK3
SCHEMBL7571560 0.84 PDK1 (0.45) POLBSMN1; SMN2PDK1PDK2PDK3
SCHEMBL2228941 0.84 FFAR1 (0.56) POLBSMN1; SMN2ALDH1A1GAAFFAR1
SCHEMBL2228937 0.84 FFAR1 (0.56) POLBSMN1; SMN2ALDH1A1GAAFFAR1
SCHEMBL2228946 0.84 FFAR1 (0.56) POLBSMN1; SMN2ALDH1A1GAAFFAR1
SCHEMBL8359192 0.82 PLA2G7 (0.38) POLBSMN1; SMN2SLC22A12ALDH1A1MEN1
SCHEMBL5441050 0.82 PLA2G7 (0.38) POLBSMN1; SMN2SLC22A12ALDH1A1MEN1
SCHEMBL7569209 0.75 BRD4 (0.43) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6465656-B2 ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-15 US disclosed
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 US disclosed
US-6329527-B1 ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles TFPI, SERPINC1, F11 P2RY2 3279/4885GPR17 3727/4885POLB 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.